MyoGene Bio

Gene editing therapy for Duchenne muscular dystrophy

Built from URL

HealthcarePharmaceuticals & MedicineBiotech

MassChallengeU.S. 2021 (winners)

AboutBuilt from URL

MyoGene Bio develops cutting-edge gene editing therapies for muscle diseases. Their lead program, MyoDys45-55, is designed to permanently fix the underlying cause of Duchenne muscular dystrophy for half of all patients using a single platform.

ProblemBuilt from URL

Duchenne muscular dystrophy is a devastating, fatal muscle wasting disease that currently has no cure.

See something off about this company?